166 related articles for article (PubMed ID: 21821012)
21. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
22. NFκB1 (p50) suppresses SOD2 expression by inhibiting FoxO3a transactivation in a miR190/PHLPP1/Akt-dependent axis.
Du K; Yu Y; Zhang D; Luo W; Huang H; Chen J; Gao J; Huang C
Mol Biol Cell; 2013 Nov; 24(22):3577-83. PubMed ID: 24068327
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.
Tapodi A; Bognar Z; Szabo C; Gallyas F; Sumegi B; Hocsak E
Biochem Pharmacol; 2019 Apr; 162():98-108. PubMed ID: 30296409
[TBL] [Abstract][Full Text] [Related]
24. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.
Nitsche C; Edderkaoui M; Moore RM; Eibl G; Kasahara N; Treger J; Grippo PJ; Mayerle J; Lerch MM; Gukovskaya AS
Gastroenterology; 2012 Feb; 142(2):377-87.e1-5. PubMed ID: 22044669
[TBL] [Abstract][Full Text] [Related]
25. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
[TBL] [Abstract][Full Text] [Related]
26. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
28. TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.
Tang L; Wang M; Jiang L; Zeng C
Hum Cell; 2020 Jul; 33(3):801-809. PubMed ID: 32388810
[TBL] [Abstract][Full Text] [Related]
29. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.
Zaczek A; Jóźwiak P; Ciesielski P; Forma E; Wójcik-Krowiranda K; Cwonda Ł; Bieńkiewicz A; Bryś M; Krześlak A
J Cell Mol Med; 2020 Jan; 24(2):1300-1310. PubMed ID: 31863623
[TBL] [Abstract][Full Text] [Related]
30. PHLPP1 Overexpression was Associated With a Good Prognosis With Decreased AKT Activity in Gastric Cancer.
Park SY; Jeong SH; Jung EJ; Ju YT; Jeong CY; Kim JY; Park T; Park J; Kim TH; Park M; Yang JW; Lee YJ
Technol Cancer Res Treat; 2022; 21():15330338211067063. PubMed ID: 34982011
[No Abstract] [Full Text] [Related]
31. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
Ying W; Sevigny MB; Chen Y; Swanson RA
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12227-32. PubMed ID: 11593040
[TBL] [Abstract][Full Text] [Related]
33. Deletion of the PH-domain and Leucine-rich Repeat Protein Phosphatase 1 (Phlpp1) Increases Fibroblast Growth Factor (Fgf) 18 Expression and Promotes Chondrocyte Proliferation.
Bradley EW; Carpio LR; Newton AC; Westendorf JJ
J Biol Chem; 2015 Jun; 290(26):16272-80. PubMed ID: 25953896
[TBL] [Abstract][Full Text] [Related]
34. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
Madison DL; Stauffer D; Lundblad JR
DNA Repair (Amst); 2011 Oct; 10(10):1003-13. PubMed ID: 21840268
[TBL] [Abstract][Full Text] [Related]
35. Roles of inhibitors of poly(ADP-ribose) polymerase in protecting rat RINm5F cell line against free fatty acid-induced apoptosis.
Mao X; Wang S; Pan Y; He B; Chen J; Jiang H; Zeng Q; Xu X
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):274-82. PubMed ID: 19513971
[TBL] [Abstract][Full Text] [Related]
36. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
37. WD repeat protein WDR48 in complex with deubiquitinase USP12 suppresses Akt-dependent cell survival signaling by stabilizing PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1).
Gangula NR; Maddika S
J Biol Chem; 2013 Nov; 288(48):34545-54. PubMed ID: 24145035
[TBL] [Abstract][Full Text] [Related]
38. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
39. Activation of telomerase by ionizing radiation: differential response to the inhibition of DNA double-strand break repair by abrogation of poly (ADP-ribosyl)ation, by LY294002, or by Wortmannin.
Neuhof D; Zwicker F; Kuepper JH; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):887-94. PubMed ID: 17889269
[TBL] [Abstract][Full Text] [Related]
40. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.
Szanto A; Hellebrand EE; Bognar Z; Tucsek Z; Szabo A; Gallyas F; Sumegi B; Varbiro G
Biochem Pharmacol; 2009 Apr; 77(8):1348-57. PubMed ID: 19426673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
